Literature DB >> 2327103

Metabolism of low-dose paracetamol in patients with chronic neurological disease.

G B Steventon1, M T Heafield, R H Waring, A C Williams, S Sturman, M Green.   

Abstract

1. Low dose (500 mg) paracetamol (acetaminophen) was administered to patients with Parkinson's disease, motor neurone disease and to age-matched controls. 2. At this low dose level the controls excreted proportionately more sulphate and less glucuronide conjugate than has been reported for administration of 1000 mg of paracetamol. 3. Both groups of patients with chronic neurological disease excreted decreased amounts of paracetamol sulphate (control mean 11.2 +/- 5.4% dose; Parkinson's disease 3.9 +/- 3.7%; motor neurone disease, 5.0 +/ 4.1%). 4. The mean ratio of excretion of paracetamol sulphate/paracetamol glucuronide was 5.6 +/- 11.7 in controls, but 1.1 +/- 1.7 and 1.2 +/- 1.7 in Parkinson's disease and motor neurone disease respectively. These differences are statistically significant (p less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2327103     DOI: 10.3109/00498259009046818

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  7 in total

1.  Ecogenetics, xenobiotic biochemistry and neurological disease.

Authors:  A Williams
Journal:  J Neurol       Date:  1991-07       Impact factor: 4.849

2.  Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism.

Authors:  T Andrew Clayton; David Baker; John C Lindon; Jeremy R Everett; Jeremy K Nicholson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

3.  Thalidomide-induced neuropathy and genetic differences in drug metabolism.

Authors:  C C Harland; G B Steventon; J R Marsden
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

4.  Paracetamol metabolism in patients with ulcerative colitis.

Authors:  K V Haderslev; J Sonne; H E Poulsen; S Loft
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

Review 5.  Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.

Authors:  H K Kroemer; U Klotz
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

Review 6.  Hereditary variation of liver enzymes involved with detoxification and neurodegenerative disease.

Authors:  A C Williams; G B Steventon; S Sturman; R H Waring
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

7.  A simple method to measure sulfonation in man using paracetamol as probe drug.

Authors:  Emília C Monteiro; Sofia A Pereira; Natália Marto; Judit Morello; Alexandra M M Antunes; Sofia Azeredo
Journal:  Sci Rep       Date:  2021-04-27       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.